This clinical trial focuses on Idiopathic Inflammatory Myopathy, also known as myositis, which is a rare condition causing muscle inflammation and weakness. The study examines the effectiveness of combining two treatments: intravenous immunoglobulin (a protein solution derived from blood that helps fight diseases) and prednisone (a steroid medication), compared to using prednisone with placebo.
The purpose of this research is to determine if adding early intravenous immunoglobulin treatment to standard prednisone therapy helps patients with newly diagnosed myositis achieve better results after 12 weeks. The medication being tested is Nanogam, which is given through an intravenous (into the vein) infusion, along with sodium chloride solution.
During the study, participants receive either the combination of immunoglobulin and prednisone or prednisone with placebo. The treatment period lasts for three months, during which patients receive multiple infusions. The study is “double blind,” which means neither the patients nor their doctors know which treatment combination each participant receives until the study is complete.



The Netherlands